# Eli lilly — media coverage

Eli lilly was mentioned 130 times in 59 outlets across 11 countries over the last 12 months. 54% of that coverage was positive and 4% negative. 93% was editorial rather than PR or paid placement.

- Data as of: 2026-10-04 (window: last 365 days)
- Mentions (12 months): 130 (135 all-time)
- Outlets (12 months): 59 in 11 countries
- Average sentiment: +0.363 (54% positive, 4% negative)
- PR / editorial: 9 PR · 121 editorial
- Sector: Pharma
- Also written as: Lilly, Mounjaro, Verzenio, Zepbound

## Coverage over time (mentions per month)

| Month | Mentions |
|---|---|
| 2025-11 | 0 |
| 2025-12 | 0 |
| 2026-01 | 1 |
| 2026-02 | 0 |
| 2026-03 | 0 |
| 2026-04 | 0 |
| 2026-05 | 2 |
| 2026-06 | 21 |
| 2026-07 | 2 |
| 2026-08 | 102 |
| 2026-09 | 2 |
| 2026-10 | 0 |

## Top outlets (12 months)

| Outlet | Mentions |
|---|---|
|  | 20 |
| finance.yahoo.com | 9 |
| fool.com | 8 |
| tradingview.com | 7 |
| investor.lilly.com | 5 |
| pharmexec.com | 5 |
| gurufocus.com | 4 |
| biospace.com | 3 |

## Countries (12 months)

| Country | Mentions |
|---|---|
| INT | 85 |
| US | 29 |
| GB | 4 |
| AU | 2 |
| CA | 2 |
| IN | 2 |
| ST | 2 |
| ES | 1 |
| MX | 1 |
| RU | 1 |

## Share of voice among Pharma peers (12 months)

| Brand | Mentions |
|---|---|
| Eli lilly | 130 |
| Astrazeneca | 78 |
| Pfizer | 64 |
| Johnson & johnson | 59 |
| Novo nordisk | 46 |
| Merck | 44 |
| Sandoz | 41 |
| Moderna | 38 |
| Bayer | 36 |
| Roche | 36 |

## Recent coverage

- [Lilly's $2.88 Billion Immunology Deal Starts in Phase 1 - GuruFocus](https://www.gurufocus.com/news/9060238/lillys-288-billion-immunology-deal-starts-in-phase-1) — gurufocus.com, 2026-09-01, neutral
- [Eli Lilly’s diabetes drug Mounjaro approved to reduce cardiovascular risks - Business Today](https://www.businesstoday.in/industry/pharma/story/eli-lillys-diabetes-drug-mounjaro-approved-to-reduce-cardiovascular-risks-552305-2026-09-01) — businesstoday.in, 2026-09-01, positive
- [Eli Lilly (LLY) Makes a $2.88 Billion Autoimmune Bet. What Could Go Right or Wrong? - Yahoo Finance](https://finance.yahoo.com/healthcare/articles/eli-lilly-lly-makes-2-234435537.html) — finance.yahoo.com, 2026-08-31, positive
- [Eli Lilly (NYSE:LLY) Gains As Metabolic Health Demand Grows - Kalkine Media](https://kalkinemedia.com/us/stocks/healthcare/eli-lilly-nyselly-gains-as-metabolic-health-demand-grows) — kalkinemedia.com, 2026-08-31, positive
- [Mounjaro Approved to Reduce Cardiovascular Risk in Type 2 Diabetes - docwirenews.com](https://www.docwirenews.com/post/mounjaro-approved-to-reduce-cardiovascular-risk-in-type-2-diabetes) — docwirenews.com, 2026-08-31, positive
- [Eli Lilly Is Acquiring Merdia Biosciences for Up to $2.88 Billion. Here's What That Means for Investors. - The Motley Fool](https://www.fool.com/investing/2026/08/31/eli-lilly-is-acquiring-merdia-biosciences-for-up-to-288-billion-heres-what-that-means-for-investors/) — fool.com, 2026-08-31, positive
- [Eli Lilly CEO Says $25B Deal Spree Is About Building Growth Beyond Obesity Into 2030s — ‘Not All These Bets Will Pay Off’ - Stocktwits](https://stocktwits.com/news-articles/markets/equity/eli-lilly-ceo-says-25-b-deal-spree-is-about-building-growth-beyond-obesity-into-2030s-not-all-these-bets-will-pay-off/cZYzbyERJsH) — stocktwits.com, 2026-08-31, neutral
- [Breadth Narrows, Software Shines; Fortinet, Edwards Lifesciences, UBS In Focus - Investor's Business Daily](https://investors.com/videos/breadth-narrows-software-shines-fortinet-edwards-lifesciences-ubs-in-focus/) — investors.com, 2026-08-31, positive

Data: VoilàIQ, 2026-10-04. Canonical: https://voilaiq.com/brand-catalog/eli-lilly